<!DOCTYPE html>
<html>

<!-- Mirrored from mullinslab.microbiol.washington.edu/publications/1334-Neutralization-titer-biomarker-for-antibody-mediated-prevention-of-HIV-1-acquisition by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 21 Jul 2025 18:05:25 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    
<title>Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition | Mullins Molecular Retrovirology Lab</title>

    
    <link rel="stylesheet" href="style.css" />
    
    <link rel="alternate" type="application/atom+xml" title="Atom feed" href="feed" />
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <script src='https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=TeX-MML-AM_CHTML' async></script>

    <!-- Global site tag (gtag.js) - Google Analytics -->
    <script async src="https://www.googletagmanager.com/gtag/js?id=UA-136625084-1"></script>
    <script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());

      gtag('config', 'UA-136625084-1');
    </script>
</head>
<body id="entry">

<div id="container">

<header>

<h1>Mullins Molecular Retrovirology Lab</h1>

<div class="description">
<ul>
<li>Department of Microbiology</li>
<li>School of Medicine</li>
<li>University of Washington</li>
</ul>

</div>


</header>

<section id="nav">
    <nav>
        
        <ul>
            <li class=""><a href="../index.html">Home</a></li>
            <li class=""><a href="../research/index.html">Research</a></li>
            <li class="here"><a href="index.html">Publications</a><ul><li><a href="supplemental.html">Supplemental Data</a></li></ul></li>
            <li class=""><a href="../protocols/index.html">Protocols</a></li>
            <li class=""><a href="../people/index.html">People</a></li>
            <li class=""><a href="../contact/index.html">Contact</a></li>
            <li class=""><a href="../help/index.html">Help</a></li>
        </ul>
    </nav>
</section>

<section id="links">
    <nav id="quicklinks">
        <h2>Software &amp; Tools</h2>

        <ul>
            <li><a href="http://indra.mullins.microbiol.washington.edu/">Bioinformatics Tools</a></li>
            <li><a href="https://github.com/mullinslab">GitHub</a></li>
            <li><a href="../hiris/index.html">HIRIS</a></li>
            <li><a href="../HMA/index.html">HMA Subtyping Kit</a></li>
            <li><a href="../isdb/index.html">ISDB</a></li>
            <li><a href="../tcozy/index.html">TCozy</a></li>
            <li><a href="https://viroverse.washington.edu/">Viroverse</a></li>
        </ul>
    </nav>

    <nav id="lablinks">
        <h2>Lab Links</h2>

        <ul>
            <li><a href="https://hercules.mullins.microbiol.washington.edu/pub/doc/">Computing Docs</a></li>
            <li><a href="../hiris/private/index.html">HIRIS (Private)</a></li>
            <li><a href="https://tcozy.mullins.microbiol.washington.edu/ice-floe/">ICE Floe</a></li>
            <li><a href="https://hercules.mullins.microbiol.washington.edu/git/">Internal Git</a></li>
            <li><a href="../twiki/index.html">Internal wiki</a></li>
            <li><a href="https://viroverse.washington.edu/viroblast/">Local ViroBLAST</a></li>
            <li><a href="https://redash.mullins.microbiol.washington.edu/">Redash</a></li>
            <li><a href="https://mullinslab.slack.com/">Slack</a></li>
            <li><a href="../support/index.html">Ticketing system</a></li>
        </ul>
    </nav>

</section>

<div id="cfar"><a href="http://cfar.washington.edu/">
    <img src="../static/_img/2c/47ca/CFAR-logo-rev-10-22-18_4aa6fe47bc_500x157.jpg" width="500" height="157" srcset="/static/_img/2c/47ca/CFAR-logo-rev-10-22-18_4aa6fe47bc_500x157.jpg 1x, /static/_img/2c/47ca/CFAR-logo-rev-10-22-18_4aa6fe47bc_1000x314.jpg 2x" alt="University of Washington/Fred Hutch Center for AIDS Research">
</a></div>

<section id="content">
    
<!-- source file: content/publications/GilbertNeutralizationTiterBiomarker.md -->
<article>

<div id="intro">
    <h1>Citation Information</h1>
<p>Peter B Gilbert, Yunda Huang, Allan C deCamp, Shelly Karuna, Yuanyuan Zhang, Craig A Magaret, Elena E Giorgi, Bette Korber, Paul T Edlefsen, Raabya Rossenkhan, Michal Juraska, Erika Rudnicki, Nidhi Kochar, Ying Huang, Lindsay N Carpp, Dan H Barouch, Nonhlanhla N Mkhize, Tandile Hermanus, Prudence Kgagudi, Valerie Bekker, Haajira Kaldine, Rutendo E Mapengo, Amanda Eaton, Elize Domin, Carley West, Wenhong Feng, Haili Tang, Kelly E Seaton, Jack Heptinstall, Caroline Brackett, Kelvin Chiong, Georgia D Tomaras, Philip Andrew, Bryan T Mayer, Daniel B Reeves, Magdalena E Sobieszczyk, Nigel Garrett, Jorge Sanchez, Cynthia Gay, Joseph Makhema, Carolyn Williamson, James I Mullins, John Hural, Myron S Cohen, Lawrence Corey, David C Montefiori, Lynn Morris (2022). <span class="title">Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition.</span> <cite class="journalName">Nature Medicine</cite> 2022 Sep.;28(9):1924-1932. (<a href="http://ncbi.nlm.nih.gov/pubmed/35995954">pubmed</a>) (<a href="https://doi.org/10.1038/s41591-022-01953-6">doi</a>)</p>
</div>


<div id="more">
    <h1>Abstract</h1>
<p>The Antibody Mediated Prevention trials showed that the broadly neutralizing antibody (bnAb) VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) sensitive to VRC01. Using AMP trial data, here we show that the predicted serum neutralization 80% inhibitory dilution titer (PT80) biomarker-which quantifies the neutralization potency of antibodies in an individual&rsquo;s serum against an HIV-1 isolate-can be used to predict HIV-1 prevention efficacy. Similar to the results of nonhuman primate studies, an average PT80 of 200 (meaning a bnAb concentration 200-fold higher than that required to reduce infection by 80% in vitro) against a population of probable exposing viruses was estimated to be required for 90% prevention efficacy against acquisition of these viruses. Based on this result, we suggest that the goal of sustained PT80 &lt;200 against 90% of circulating viruses can be achieved by promising bnAb regimens engineered for long half-lives. We propose the PT80 biomarker as a surrogate endpoint for evaluation of bnAb regimens, and as a tool for benchmarking candidate bnAb-inducing vaccines.</p>
</div>


<div class="clear"></div>
</article>

</section>

</div>
</body>
<!-- Mirrored from mullinslab.microbiol.washington.edu/publications/1334-Neutralization-titer-biomarker-for-antibody-mediated-prevention-of-HIV-1-acquisition by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 21 Jul 2025 18:05:25 GMT -->
</html>